Navigation Links
U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa
Date:4/23/2013

s and we are also interested in providing prevention of relapses and improvement of treatment outcomes in patients with an ongoing Pa infection," according to Michel DeWilde , Ph.D., Senior Vice President, Research and Development. "Additional indications may be considered later in the lifecycle of the product."

Under the terms of the current agreement, Sanofi Pasteur has worldwide rights to KaloBios' KB001A technology for all disease indications related to Pa infections, except cystic fibrosis and bronchiectasis, the rights in which were retained by KaloBios, and Sanofi Pasteur has the option to obtain at a later date.  

"Hospital-based pneumonias, especially those associated with mechanically ventilated patients in the ICU, are a life-threatening complication that can significantly increase mortality and morbidity as well as add tens of thousands of dollars to the cost of a hospital stay," said David Pritchard , President and CEO, KaloBios. "KB001's novel mechanism of action against Pa may provide a unique means of fighting these infections, which are often resistant to antibiotic therapies. The FDA fast-track designation recognizes that this novel biologic could address an important unmet medical need."

About KB001A

KB001A, a Humaneered™ antibody fragment, is designed to fight Pseudomonas aeruginosa (Pa) by blocking a virulence mechanism (the Type Three Secretion System or TTSS) on the bacterium's external surface that enables Pa to evade human immune defenses by killing white blood cells and epithelial cells, and triggering tissue-damaging inflammation. By blocking Pa's killing mechanism, KB001A is intended to reduce the damage done to the lungs by Pa and potentially enable the patie
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. R&D Systems is Offering Travel Grants to Attend the 15th International Congress of Immunology
2. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
3. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
4. Immunology 2013™ Travel Grants Available from R&D Systems
5. SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
6. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
7. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
8. USPTO Grants Butamax a Further KARI Enzyme Patent
9. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
10. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
11. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... manufacture parts and assemble MOD® units, an innovative medication dispenser produced ... ... February 15, 2009 -- Zeus, Inc., a global leader in the ... new partnership with Avancen MOD Corporation. Avancen produces the MOD ...
... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
... Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) ... the biopharmaceutical industry, it has maintained its focus ... of sustained profitability. The Company was announcing results ... , In a news release today, William J. ...
Cached Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... MAIncreasing nitrogen runoff from urban and agriculture land-use is ... reducing this pollutant before it endangers delicate downstream ecosystems, ... from the MBL (Marine Biological Laboratory) Ecosystems Center. ... issue of Nature, are based on a major study ...
... returning to beaches will face the reality of "red tide" ... swimming and pose risks to humans and sea life. ... running through their neighborhoods play a critical role in filtering ... new study published in this week,s edition of the journal ...
... Healthy streams play a major role in minimizing the ... delivered downstream. This ecosystem service is valuable; excess nitrogen ... and depleting the water of oxygen. This phenomenon, also ... This week, a team of scientists that included ...
Cached Biology News:Increasing nitrogen pollution overwhelms filtering capability of streams 2From the backyard to the ocean: New study shows streams act as key nitrogen filters 2Small streams mitigate human influence on coastal ecosystems 2
Cytofix Buffer 100 mls...
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Biology Products: